Innovent has 10 products in the market, including TYVYT (Sintilimab Injection), BYVASDA (Bevacizumab Injection), SULINNO (Adalimumab Injection), HALPRYZA (Rituximab Injection), Pemazyre (Pemigatinib Oral Inhibitor), Olverembatinib, Cyramza (Ramucirumab Injection), Retsevmo (Selpercatinib Capsules ), FUCASO (Equecabtagene Autoleucel Injection) and SINTBILO (Tafolecimab Injection).Additionally, we have 2 assets are under NMPA NDA review, 5 assets are in Phase III or pivotal clinical trials, and 19 more molecules in early clinical stage
These help to understand the wound better
These definitive findings underscore L-carnitine's vital, irreplaceable role in supporting heart muscle energy, which is a critical consideration for patients desperately trying to manage the severe cardiovascular symptoms of dysautonomia and POTS
The regulatory perception of these two formulations is more like this image than clinical measurement
For many women, the difference matters